Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Double-Blind, Double-Dummy Phase 2 Randomized Study to Evaluate the Efficacy and Safety of Ruxolitinib Versus Anagrelide in Subjects With Essential Thrombocythemia Who Are Resistant to or Intolerant of Hydroxyurea (RESET-272)

NCT03123588 is registered in ClinicalTrials.gov with Incyte Corporation as lead sponsor.

NCT NCT03123588
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03123588 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Double-Blind, Double-Dummy Phase 2 Randomized Study to Evaluate the Efficacy and Safety of Ruxolitinib Versus Anagrelide in Subjects With Essential Thrombocythemia Who Are Resistant to or Intolerant of Hydroxyurea (RESET-272)
Lead sponsor
Incyte Corporation
Phase
Phase 2
Overall status
Terminated
Start date
November 14, 2017
Completion date
August 3, 2020
Enrollment
12 (actual)
Sites
26

Conditions

As the registry lists them; a condition with its own page is linked.

mpn (myeloproliferative neoplasms)